Navigation Links
Halozyme to Host Third Quarter 2013 Financial Results Conference Call
Date:11/1/2013

SAN DIEGO, Nov. 1, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2013 on Friday, November 8, 2013 at 8:30 a.m. ET/5:30 a.m. PT. Gregory I. Frost, President and Chief Executive Officer, will lead the call. On the same date pre-market, Halozyme will release financial results for the third quarter 2013.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to www.halozyme.com approximately fifteen minutes prior to the call to register, download, and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using replay ID number 423197.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com and follow us on www.twitter.com/HALOTherapeutic.

Investor Contact:
David Ramsay
Halozyme Therapeutics
858-704-8260
ir@halozyme.com

Media Contact:
Nurha Hindi
Hill + Knowlton Strategies
818-522-8411
Nurha.Hindi@hkstrategies.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. SWOG Initiates Randomized Phase 2 Clinical Trial of Halozymes PEGPH20 in Combination with modified FOLFIRINOX for Advanced Pancreatic Cancer
2. Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013
3. Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to Halozyme from Roche
4. Halozyme Therapeutics To Present At The BioCentury Newsmakers In The Biotech Industry Conference
5. Halozyme to Present New Data on PEGPH20 in Pancreatic Cancer at European Cancer Congress
6. Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
7. Halozyme Reports Second Quarter 2013 Financial Results
8. Halozyme Provides Update on ViroPharma Phase 2 Trial of Subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) Formulation with rHuPH20
9. Halozyme to Host Second Quarter 2013 Financial Results Conference Call
10. Halozymes Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer
11. Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016 ... addition of the "Global Obstetrics Partnering ... company profile to their offering. --> ... of the "Global Obstetrics Partnering 2010-2016: ... profile to their offering. --> ...
(Date:2/4/2016)...   Bernstein Liebhard LLP today announced that a ... District Court for the District of Arizona ... all persons or entities who purchased common shares of Insys ... from March 3, 2015 through January 25, 2016 (the "Class ... with violations of the Securities Exchange Act of 1934.  ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... and competitive market to drive long-term market growth ... very common set of chronic disorders that affect ... disparate in terms of their symptoms and key ... by dysregulation of immune pathways and an inappropriate ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... 05, 2016 , ... Freed-Hardeman University President Joe A. Wiley ... joint enrollment and degree completion agreement. The agreement, which begins with the ... FHU|Dickson. , The agreement allows students to be jointly admitted to both ...
(Date:2/5/2016)... ... February 05, 2016 , ... The American public tends to feel ... be safer than regular municipal or well water. The recent experience with lead contaminated ... could go a long way toward increasing public acceptance of recycled waste water as ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... announced the election of Patrick McDermott as Chairman of the National Board of Directors. ... Pat as Chairman of the Board,” stated Leslie A. Chambers , APDA President ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the defenses of the ... hallmark feature of patients with eating disorders is significant self-criticism, and consequently these patients ... obsessions are regarded as maladaptive means for coping with this unease, but also leads ...
(Date:2/5/2016)... Boston, MA (PRWEB) , ... February 05, 2016 ... ... hosted its inaugural Columbia University Men’s Soccer Career Development event in New York ... KICVentures, and Rocco Commisso, Chairman and CEO of Mediacom, (both alumnus of the ...
Breaking Medicine News(10 mins):